Keirstead is working with human embryonic stem cells to treat spinal cord injury.

FORBES: Magazine Article

This morning, Geron of Menlo Park, for years a leading company in embryonic stem cell research, announced that the first patient had been dosed in a study of its embryonic stem cell treatment for spinal cord injury.

FORBES: Don't Get Too Excited About The First Embryonic Stem Cell Patient

The petition says that she suffered "brain stem contusion injuries with associated cervical cord injury and due to this she was reduced to almost a vegetable".

BBC: India doctors to examine 'euthanasia' woman

Another common property of stem cells is to accumulate at sites of injury, where their services are obviously needed.

ECONOMIST: Stem cells

Geron's treatment for spinal cord injury was the first human embryonic stem cell therapy to receive FDA approval for a clinical trial.

FORBES

And Geron of Menlo Park, Calif. is performing animal studies on a variety of different cells derived from human embryonic stem cells, aiming to treat spinal cord injury, heart disease and diabetes.

FORBES: Magazine Article

And Geron (nasdaq: GERN - news - people ) of Menlo Park, Calif. is performing animal studies on a variety of different cells derived from human embryonic stem cells, aiming to treat spinal cord injury, heart disease and diabetes.

FORBES: Despite Bush Veto, Stem Cell Research Abounds

The lead company developing the cells as treatments, Geron, just recently started the very first trial of embryonic stem cells in humans, to treat spinal cord injury.

FORBES: How Politics Body Slams Science

Douglas Kerr, a scientist at Johns Hopkins, which is using money from billionaire Bloomberg to create a stem-cell lab, says the lack of NIH help could delay a treatment for spinal cord injury for decades.

FORBES: Anti-Ban Billionaires